<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681795</url>
  </required_header>
  <id_info>
    <org_study_id>15 7836 03</org_study_id>
    <secondary_id>2017-000816-40</secondary_id>
    <nct_id>NCT03681795</nct_id>
  </id_info>
  <brief_title>Exploration of Glutamatergic System With PET Radiotracer in Gilles de la Tourette Patients: Pilot Study (GlutaTour)</brief_title>
  <acronym>GlutaTour</acronym>
  <official_title>Exploration of Glutamatergic System With PET Radiotracer in Gilles de la Tourette Patients: Pilot Study (GlutaTour)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gilles de la Tourette syndrome is a neuropsychiatric disorder characterized by motor and
      vocal tics often associated with psychiatric comorbidities (obsessive compulsive disorder,
      anxiety and depressive syndrome, impulsivity). The pathophysiology of Gilles de la Tourette
      syndrome remains unclear.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gilles de la Tourette syndrome is a neuropsychiatric disorder characterized by motor and
      vocal tics often associated with psychiatric comorbidities (obsessive compulsive disorder,
      anxiety and depressive syndrome, impulsivity). The pathophysiology of Gilles de la Tourette
      syndrome remains unclear. It would involve an alteration of striatal-cortico-thalamic
      cortical circuits resulting in dopaminergic dysfunction. But glutamaergic hypothesis is also
      discussed from pharmacological, biochemical and genetic arguments. Exploration of
      glutamatergic system can be done in humans in vivo using a new radiotracer: the [18F] FNM
      (Fluoroéthylnormémantine), a derivative of memantine. In the present study, aim of the study
      1) to show the glutamatergic system &quot;in vivo&quot; in patients with Tourette's syndrome and 2) to
      perform correlations between various motor and behavioral symptoms and the pattern of brain
      fixation for this radiotracer. To do that, a pilot study will be conducted in 12 patients
      with Tourette's who will be evaluated in terms of motor (tics) and behavioral (OCD, anxiety,
      depression, impulsivity) symptoms. Each patient will have a PET-scan exam and a brain MRI
      exam. Data analysis will be carried out from two different approaches: first by region of
      interest, and secondly, without topographic a priori with the SPM software.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation coefficients</measure>
    <time_frame>Day 1</time_frame>
    <description>Correlation coefficients between the radiotracer fixation and patients' score on the TIS (subscore of the Yale Global Tic Severity Scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yale Global Tic Severity Scale</measure>
    <time_frame>Day 1</time_frame>
    <description>Correlation coefficients between the radiotracer fixation and patients' scores on the Yale Global Tic Severity Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>Day 1</time_frame>
    <description>Correlation coefficients between the radiotracer fixation and patients' scores on the Yale Brown Obsessive Compulsive Scale (Y-BOCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety Depression</measure>
    <time_frame>Day 1</time_frame>
    <description>Correlation coefficients between the radiotracer fixation and patients' scores on the ), Hospital Anxiety Depression (HAD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barrat Impulsivity Scale 11</measure>
    <time_frame>Day 1</time_frame>
    <description>Correlation coefficients between the radiotracer fixation and patients' scores on the Barrat Impulsivity Scale 11</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Gilles de la Tourette Syndrome</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental MRI exam and PET scan exam without comparator. Patients evaluated on motor and behavioral symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Experimental MRI exam and PET scan exam</intervention_name>
    <description>MRI exam and PET scan exam</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gilles de la Tourette syndrome according to the American Psychiatric association
             criteria (5 th ed, APA, 2013)

          -  Aged 18 and over

          -  Patients treated with 2nd-generation neuroleptics for at least 3months

          -  Signed consent form

        Exclusion Criteria:

          -  contraindications for MRI exam

          -  claustrophobia

          -  person under exclusive period for another study

          -  pregnant women

          -  patients under non-authorized treatment (1rst generation neuroleptics) or non-treated
             by neuroleptics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine BREFEL-COURBON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine BREFEL-COURBON, MD</last_name>
    <phone>05 61 77 94 91</phone>
    <phone_ext>33</phone_ext>
    <email>christine.brefel-courbon@univ-tlse3.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pierre-Paul Riquet - CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine BREFEL-COURBON, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>September 20, 2018</last_update_submitted>
  <last_update_submitted_qc>September 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gilles de la Tourette syndrome</keyword>
  <keyword>glutamaergic system</keyword>
  <keyword>PET-scan</keyword>
  <keyword>physiopathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

